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Background and importance Pneumatic delivery is not recom-
mended for medicinal products that could undergo physical
alteration of the active ingredient, such as protein denatura-
tion (Peak, 2003). A review of the literature reveals that the
solution air–liquid interface and number of travel cycles can
be risk determining factors for compounded stability of mono-
clonal antibodies after pneumatic delivery (Vieillard et al,
2012; Vieillard et al, 2013; Vieillard et al, 2014). In our hos-
pital, all compounded monoclonal antibodies are delivered via
a pneumatic system to the oncologic day hospital unit from
the pharmacy compounding department.
Aim and objectives To investigate the stability of nivolumab
compounded solution after pneumatic delivery, and the effect
of residual air inside the infusion bag.
Material and methods The following nivolumab samples,
diluted to 2.4 mg/mL in a prefilled 0.9% sodium chloride pol-
yolefin infusion bag, were prepared: sample nivolumab, not
undergoing pneumatic delivery, sample PNA, with residual air,
and sample PN, without residual air, both undergoing single
travel inside the pneumatic delivery system. On the day of
preparation, all samples were analysed for pH, osmolality, tur-
bidimetry, dynamic light scattering (DLS), size exclusion chro-
matography-high performance liquid chromatography (SEC-
HPLC) and nuclear magnetic resonance (NMR).
Results All samples were clear, without particulate or precipi-
tates, and turbidity free at 350 nm. pH values shifted from
5.77 to 5.92. Osmolality values ranged from 286 and 296
mOsm/kg. DLS revealed a monodisperse peak at about 11
nm, with similar shape and intensity. SEC-HPLC did not
reveal any peak retention time variations, and NMR did not
reveal any modifications regarding peak shape or intensity.
Conclusion and relevance No difference in physical or chemical
stability was found between compounded nivolumab solutions
not undergoing and undergoing single travel inside the pneu-
matic system. The presence of the air–liquid interface inside
the solution bag was not risk determining for solution stabil-
ity. The pneumatic delivery system at our hospital can be used
for delivery of compounded nivolumab solution to the onco-
logic day hospital.
REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
3PC-017 INCREASING PHARMACY PRODUCTIVITY BY
EXPANDING THE ROLE OF THE INTRAVENOUS
COMPOUNDING ROBOT IN A COMPREHENSIVE
CANCER CENTRE
1M Capilli*, 2M Federici, 3T Comandone, 1G Maffeis, 4F Foglio, 4L Omini, 4F Enrico.
1University of Turin, Drug Science and Technology-School of Specialisation in Hospital
Pharmacy, Turin, Italy; 2Loccioni, Angeli Di Rosora, Ancona, Italy; 3University of Turin, Drug
Science and Technology, Turin, Italy; 4Fpo Irccs Candiolo, Hospital Pharmacy, Candiolo, Italy
10.1136/ejhpharm-2020-eahpconf.64
Background and importance In a comprehensive cancer centre,
injectable anticancer drugs are compounded in the pharmacy
based preparation unit with the compounding robot APOTE-
CAchemo to guarantee a high level of quality and safety. In
2018, the oncology pharmacy implemented workflow improve-
ments to manage the growing workload due to the centralisa-
tion of the activities of a hospital’s satellite pharmacy.
Aim and objectives The aim of the study was to analyse the
pharmacy workflow and impact of the robotic system on turn-
around time to meet increasing pharmacy productivity.
Material and methods Data were collected from the hospital
information system and the workflow management software
APOTECAmanager, and examined over a 2 year period
(2017–2018). The total annual throughput in terms of doses
prepared and patients treated were determined. Productivity,
number of active ingredients processed, average usage time
per day and dosage accuracy (ie, per cent discrepancy between
compounded and prescribed dose) were calculated for the
robotic system. Medication turnaround time (MTAT) for out-
patients, defined as total time from the release of a medica-
tion order by the prescriber to administration of the
medication to the patient, was measured over 3 months.
Results Overall, the annual doses prepared and patients treated
increased by 18% (from 18 574 doses/year in 2017 to 22
754 doses/year in 2018) and by 10% (from 1421 patients/year
in 2017 to 16 604 patients/year in 2018), respectively. The
robot was used to compound 47% of the overall doses pre-
pared in 2017 (8677 doses/year) compared with 57% in 2018
(13 047 doses/year). The average usage time of the robot
increased by 58% (from 2.09 hours/day in 2017 to 5.01
hours/day in 2018), while the number of active ingredients
processed rose from 20 in 2017 to 30 in 2018. Overall,
95.0% of doses prepared with the robot showed an error
<2.0%. The average MTAT for outpatients was lowered by
24.7% (from 2.8 hours in 2017 to 2.1 hours in 2018).
Conclusion and relevance The study revealed that the oncology
pharmacy was able to meet escalating demands of ready to
administer anticancer drugs by satellite hospitals, by making
more use of the robotic system without increasing pharmacy
staff. The pharmacy workflow changes enabled reduced MTAT
and better order processing efficacy, thereby providing
improved patient care.
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Background and importance Mitomycin C is used in different
regimens for the treatment of bladder, anus and lung cancer.
According to the data sheet, reconstitution of the vial should
be carried out with water for preparation of injectables or
with 20% dextrose. Despite this, sodium chloride solutions
are commonly used for its administration. However, it is
known that the stability of mitomycin C molecule is affected
by the pH of the preparation as degradation increases with
pH values <7. Sodium chloride solutions have an approximate
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